Literature DB >> 25645642

Attention deficit/hyperactivity disorder and interictal epileptiform discharges: it is safe to use methylphenidate?

Dobrinko Socanski1, Dag Aurlien2, Anita Herigstad3, Per Hove Thomsen4, Tor Ketil Larsen5.   

Abstract

PURPOSE: This study investigated whether interictal epileptiform discharges (IED) on a baseline routine EEG in children with ADHD was associated with the occurrence of epileptic seizures (Sz) or influenced the use of methylphenidate (MPH) during 2 years follow-up.
METHODS: A retrospective chart-review of 517 ADHD children with EEG revealed IED in 39 cases. These patients (IED group) were matched on age and gender with 39 patients without IED (non-IED group). We measured at baseline, 1 year and 2 years Sz occurrence, the use of MPH and antiepileptic drug (AED).
RESULTS: At baseline, 12 patients in the IED group had active epilepsy and three of them had Sz during the last year. 36 (92.3%) patients were treated with MPH. Initial positive response to MPH was achieved in 83.3% compared with 89.2% in the non-IED group. At 1 and 2 years follow-up, three patients who also had Sz at baseline and difficult to treat epilepsy, had Sz, without changes in seizure frequency. We found no statistically significant differences between the groups with respect to MPH use at 1 year and at 2 years. Ten patients from IED group, who did not have confirmed epilepsy diagnosis, temporarily used AEDs during the first year of follow-up.
CONCLUSION: Despite the occurrence of IED, the use of MPH was safe during 2 years follow-up. IED predict the Sz occurrence in children with previous epilepsy, but does not necessarily suggest an increased seizure risk. A caution is warranted in order not to overestimate the significance of temporarily occurrence of IED.
Copyright © 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antiepileptic drug (AED); Attention-deficit/hyperactivity disorder (ADHD); Epilepsy; Interictal epileptiform discharges (IED); Methylphenidate (MPH)

Mesh:

Substances:

Year:  2015        PMID: 25645642     DOI: 10.1016/j.seizure.2015.01.002

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  3 in total

1.  Paying Attention to Quality of Life: Epilepsy and Attention Deficit Hyperactivity Disorder.

Authors:  Jay Salpekar
Journal:  Epilepsy Curr       Date:  2018 Jul-Aug       Impact factor: 7.500

2.  Long-term use of methylphenidate in a boy with hypothalamic tumor, drug-resistant epilepsy and ADHD.

Authors:  Dobrinko Socanski; Nebojsa Jovic; Harald Beneventi; Anita Herigstad
Journal:  Epilepsy Behav Case Rep       Date:  2018-04-20

Review 3.  Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.

Authors:  Ole Jakob Storebø; Nadia Pedersen; Erica Ramstad; Maja Lærke Kielsholm; Signe Sofie Nielsen; Helle B Krogh; Carlos R Moreira-Maia; Frederik L Magnusson; Mathilde Holmskov; Trine Gerner; Maria Skoog; Susanne Rosendal; Camilla Groth; Donna Gillies; Kirsten Buch Rasmussen; Dorothy Gauci; Morris Zwi; Richard Kirubakaran; Sasja J Håkonsen; Lise Aagaard; Erik Simonsen; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2018-05-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.